Keeping Track: Dueling 'Breakthroughs' For Peanut Allergy

The latest drug development news and highlights from our FDA Performance Tracker.

The list of "breakthrough" therapy designations continues to grow as FDA deems a second peanut allergy desensitization treatment worthy of the status, while Keeping Track also notes new submissions for autoimmune disease, acromegaly and migraine.

FDA has granted its second "breakthrough" therapy designation for a peanut allergy treatment in three months, setting the stage for...

More from Clinical Trials

More from R&D